Category Archives: Antibiotics

Dr. Clay Siegall and Seattle Genetics Are Focused on Helping Cancer Patients

Dr. Clay Siegall is a distinguished and well-respected professional in his field of biotechnology. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He currently serves as the President, the Chief Executive Officer and the Chairman on the Board of Seattle Genetics, Inc. He co-founded the company in 1998 to help focus on the unmet medical needs in oncology. The biotechnology company develops and commercializes antibody-based therapies for the treatment of cancer.

He spearheaded Seattle Genetics capital-raising programs securing more than $1.2 billion which includes the company’s initial public offering. These monies have helped develop antibody-based cancer therapies such as ADCETRIS which was approved by the U.S. Food and Drug Administration in 2011 and is available in 65 countries. Furthermore, the product is under clinical development for expansion into treatment for CD30-expressing lymphomas. ADCETRIS was developed in collaboration with Takeda Pharmaceutical Company Limited. Seattle Genetics continues to collaborate with other biotechnology and pharmaceutical companies in oncology in order to address the needs of cancer patients.

Dr. Siegall brings a wealth of knowledge to his position due to his broad pharmaceutical industry experience. He worked for the National Cancer Institute from 1988 to 1991 and for the Bristol-Myers Squibb Pharmaceutical Research Institute for the following six years before establishing Seattle Genetics.

He also serves on the Board of Directors of Ultragenx Pharmaceutical, Alder Biopharmaceuticals, Washington Roundtable and Mirna Therapeutics. The latter is a biotechnology company focused on the development and commercialization of microRNA to help combat cancer tumors.

Dr. Siegall has received numerous accolades, including the University of Maryland Alumnus of the Year for Computer, Math and Sciences in 2013 and the Northwest Ernst & Young Entrepreneur of the Year in 2012. In addition, he holds 15 patents and has authored more than 70 publications.

We’re Addicted to Antibiotics and It’s Causing Us Harm

Let’s face it, we as a society have a real phobia of bacteria. Add that to our love of pharmaceuticals and an antibiotic addiction is born. The problem is antibiotics aren’t effective for a lot of ailments and the more we use them, the more ineffective they become. More and more organisms the antibiotics are designed to eradicate are becoming resistant to them.

According to the CDC, up to two million people in the United States each year are infected with bacteria that is resistant to antibiotics and approximately 23,000 die each year as a result. People no longer have any tolerance for illness. They want a solution quickly. so they turn to pharmaceuticals. Zeca Oliveira has found that the problem is pharma companies are reluctant to develop newer kinds of antibiotics since these medicines don’t bring in as much profit.

Complete resistance to antibiotics is a very real danger in the not so distant future. It’s up to doctors to educate patients about the use of antibiotics, especially where viruses are concerned. Most patients do not understand that antibiotics are not effective in killing a virus and in most cases our bodies are completely capable of dealing with the illness without the use of drugs.

With antibiotic resistance, disease is much more likely to spread. This is a dangerous situation for the populous at large. Better to let our immune systems deal with our minor ailments and ride the symptoms out. It might not be pleasant in the short term, but in the long term it’ll help keep disease at bay.